This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.
FDA sets standard review for Gilead's idelalisib in NHL. Comes despite accelerated review for drug's use in chronic lymphocytic leukaemia. ... The US Food and Drug Administration ( FDA) has started its review of Gilead Sciences' marketing application for
its PI3K inhibitor idelalisib, which was superior to MabThera in a CLL trial reported last year.
In the coming years its toughest competition is likely to be from Gilead Sciences' PI3K inhibitor idelalisib, which is currently under accelerated regulatory review in the US.
If approved in CLL, Imbruvica's toughest competition is likely to be from Gilead Sciences, whose PI3K inhibitor idelalisib is in late-stage testing but has not yet been filed for approval. ... Last October, Gilead halted a phase III trial in CLL early
Gilead halts leukaemia study on positive results. Idelalisib provides significant benefit in chronic lymphocytic leukaemia. ... A pivotal trial of Gilead Sciences' idelalisib in patients with chronic lymphocytic leukaemia ( CLL) is to be stopped after
clinical pipeline, notably Pharmacyclics/Johnson &Johnson's i brutinib and Gilead Sciences' idelalisib.